Idaho News Updates

Delveinsight Business Research LLP

Several major pharma giants such as GlaxoSmithKline, Mirum Pharmaceuticals, Albireo Pharma, Intercept Pharmaceuticals, Cymabay Therapeutics, Care Therapeutics, and others are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the QoL of patients with Cholestasis.

DelveInsight’s “Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cholestatic Pruritus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Cholestatic Pruritus drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cholestatic Pruritus treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Cholestatic Pruritus: An Overview

Cholestasis is defined as impaired secretion of bile. Pruritus is a complication of cholestasis including that associated with mutations in genes that code for transporters in the hepatocyte and from inflammatory liver diseases. Pruritus is a debilitating symptom reported among 80% to 100% of patients with cholestatic liver disease, including primary biliary cholangitis, primary sclerosing cholangitis, and intrahepatic cholestasis of pregnancy. 

Cholestatic pruritus is severe. Although there is no primary rash associated with cholestatic pruritus, patients who have cholestatic itch often present with secondary lesions from scratching in an attempt to alleviate pruritus. Cholestatic pruritus can occur at any stage of liver disease. Its intensity is often exacerbated by psychological stress, heat, and contact with wool. 

Cholestatic Pruritus Market Key Facts

• As per the Royal College of Obstetricians and Gynaecologists, United Kingdom, obstetric cholestasis is a multifactorial condition of pregnancy characterized by pruritus in the absence of a skin rash with abnormal liver function tests. In England, this condition affects nearly 1% of pregnancies in multiethnic populations.

• A study conducted by Dull and Kremer (2020) titled “Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease”, suggests that patients with genetic biliary disorders such as BRIC or PFIC commonly suffer from cholestatic itch. Chronic pruritus is characteristic of the immune-mediated cholestatic disorders PBC, PSC, and SSC, with a lifetime prevalence of up to 70–80%. 

Cholestatic Pruritus Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Cholestatic Pruritus pipeline therapies. It also thoroughly assesses the Cholestatic Pruritus market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Cholestatic Pruritus drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Cholestatic Pruritus Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Cholestatic Pruritus epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Cholestatic Pruritus epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Cholestatic Pruritus Epidemiology, Segmented as –

• Total Prevalent Population of Cholestatic Pruritus in the 7MM (2019–2032)

• Severity-specific Prevalent Population of Cholestatic Pruritus in the 7MM (2019–2032)

• Gender-specific Prevalent Population of Cholestatic Pruritus in the 7MM (2019–2032)

• Diagnosed and Treatable Population of Cholestatic Pruritus in the 7MM (2019–2032)

Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cholestatic Pruritus market or expected to be launched during the study period. The analysis covers the Cholestatic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Cholestatic Pruritus drugs based on their sale and market share.

The report also covers the Cholestatic Pruritus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Cholestatic Pruritus companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Cholestatic Pruritus Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/cholestatic-pruritus-market

Cholestatic Pruritus Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Cholestatic Pruritus. Currently, GlaxoSmithKline is leading the therapeutics market with its Cholestatic Pruritus drug candidates in the most advanced stage of clinical development.

“On 13 June 2023, Ipsen (Euronext: IPN: ADR: IPSEY) announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS). Bylvay was approved as the first drug treatment option for patients living with cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) in the U.S. and for the treatment of PFIC in Europe, in 2021. Bylvay is immediately available via prescription for eligible ALGS patients.”

Cholestatic Pruritus Companies Actively Working in the Therapeutics Market Include

• Escient Pharmaceuticals

• Cara Therapeutics

• GlaxoSmithKline

• CymaBay Therapeutics

• Mirum Pharmaceuticals

And Many Others

Emerging and Marketed Cholestatic Pruritus Therapies Covered in the Report Include:

• Volixibat: Mirum Pharmaceuticals

• Linerixibat: GlaxoSmithKline

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/cholestatic-pruritus-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Cholestatic Pruritus Competitive Intelligence Analysis

4. Cholestatic Pruritus Market Overview at a Glance

5. Cholestatic Pruritus Disease Background and Overview

6. Cholestatic Pruritus Patient Journey

7. Cholestatic Pruritus Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Cholestatic Pruritus Treatment Algorithm, Current Treatment, and Medical Practices

9. Cholestatic Pruritus Unmet Needs

10. Key Endpoints of Cholestatic Pruritus Treatment

11. Cholestatic Pruritus Marketed Therapies

12. Cholestatic Pruritus Emerging Drugs and Latest Therapeutic Advances

13. Cholestatic Pruritus Seven Major Market Analysis

14. Attribute Analysis

15. Cholestatic Pruritus Market Outlook (In US, EU5, and Japan)

16. Cholestatic Pruritus Companies Active in the Market

17. Cholestatic Pruritus Access and Reimbursement Overview

18. KOL Views on the Cholestatic Pruritus Market

19. Cholestatic Pruritus Market Drivers

20. Cholestatic Pruritus Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/cholestatic-pruritus-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Gene Therapy for Ocular Rare Disease Market

“Gene Therapy for Ocular Rare Disease  Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Gene Therapy for Ocular Rare Disease market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Gene Therapy for Ocular Rare Disease Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/